NANO REVIEWS & EXPERIMENTS, 2017
VOL. 8, 1331100
https://doi.org/10.1080/20022727.2017.1331100

REVIEW ARTICLE

Nano-sized carriers in gene therapy for peritoneal fibrosis in vivo
Yusuke Igarashi\textsuperscript{a}, Taro Hoshino\textsuperscript{b}, Susumu Ookawara\textsuperscript{b}, Kenichi Ishibashi\textsuperscript{b} and Yoshiyuki Morishita\textsuperscript{a}

\textsuperscript{a}Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Tochigi, Japan; \textsuperscript{b}Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan

ABSTRACT
Peritoneal fibrosis is a crucial complication in patients receiving peritoneal dialysis. It is a major pathological feature of peritoneal membrane failure, which leads to withdrawal of peritoneal dialysis. No specific therapy has yet been established for the treatment of peritoneal fibrosis. However, gene therapy may be a viable option, and various nano-sized carriers, including viral and non-viral vectors, have been shown to enhance the delivery and efficacy of gene therapy for peritoneal fibrosis in vivo. This review focuses on the use of nano-sized carriers in gene therapy of peritoneal fibrosis in vivo.

ARTICLE HISTORY
Received 25 January 2017
Accepted 11 May 2017

KEYWORDS
Peritoneal fibrosis; gene therapy; viral vector; non-viral vector

1. Introduction
Peritoneal dialysis is a home-based renal replacement therapy for patients with end-stage renal disease [1]. The procedure involves injecting a peritoneal dialysis solution into the abdominal cavity through an inserted peritoneal dialysis catheter and using the peritoneum as a dialysis membrane for ultrafiltration and solute clearance [1]. Peritoneal dialysis has certain advantages over hemo dialysis, such as convenience, economy, and a shorter dialysis time [1,2]. However, peritoneal membrane failure represents a major obstacle to continued long-term peritoneal dialysis [3–6]. Peritoneal membrane failure manifests as deleterious structural and functional alterations caused by exposure to bio-incompatible peritoneal dialysis solutions [3–6]. Peritoneal fibrosis is a major pathological feature of peritoneal membrane failure [6–8], characterized histologically by myofibroblast proliferation and excess accumulation of extracellular matrix, including collagen, in the peritoneal mesothelium [9,10]. No specific therapy has yet been established for the treatment of peritoneal fibrosis. However, numerous cell types, including mesothelial cells, bone marrow-derived cells, endothelial cells, and fibroblasts, have been reported to contribute to its development [11], and \textit{in vivo} studies aimed at improving our understanding of the potential therapeutic approaches for peritoneal fibrosis are urgently required. Gene therapy may be a potential therapeutic option because it can target novel molecules that were previously difficult to target using small molecules or antibodies. Various nano-sized carriers, including viral and non-viral vectors, have been shown to enhance the delivery and treatment effects of gene therapy [12,13]. This review focuses on the use of nano-sized carriers in gene therapy of peritoneal fibrosis in vivo.

2. Mechanism of peritoneal fibrosis development
The mechanism of peritoneal fibrosis is shown in Figure 1. Repeated exposure to peritoneal dialysis solutions containing high concentrations of glucose is considered to play a central role in the development of peritoneal fibrosis in patients undergoing peritoneal dialysis [3–6]. Glucose is degraded to glucose-degradation products including methylglyoxal, glyoxal, formaldehyde, and 3-deoxyglucosone during heat sterilization [14–16], and these products are further transformed to advanced glycation end-products [14,15,17–19]. Both the glucose-degradation products and advanced glycation end-products have been reported to activate transforming growth factor (TGF)-\(\beta_1\) signaling in the peritoneal membrane, thus promoting peritoneal fibrosis [14,15,17–20]. Activated TGF-\(\beta_1\) promotes the proliferation of fibroblasts from different origins, including mesothelial cells via mesothelial–mesenchymal transition, bone marrow-derived cells, and endothelial cells, in addition to resident fibroblasts [21–24]. TGF-\(\beta_1\) also increases the production of various extracellular matrix and fibrogenesis-associated molecules such as Snail, fibronectin, collagen I, and \(\alpha\)-smooth muscle actin (\(\alpha\)-SMA) on the peritoneal membrane, leading to peritoneal...
fibrosis [21–24]. Both glucose-degradation products and advanced glycation end-products have also been reported to promote chronic inflammation characterized by infiltration of macrophages [25,26], which in turn secrete pro-fibrotic cytokines such as tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-6, as well as TGF-β1 [27–31]. These cytokines induce peritoneal fibrosis by promoting fibroblast proliferation and type I collagen synthesis on the peritoneum [32,33].

3. Nano-sized carriers for gene therapy of peritoneal fibrosis in vivo

Various nano-sized carriers, including viral and non-viral vectors, have been studied for the gene therapy of peritoneal fibrosis (Figure 2) [34–45]. The different categories of vectors, transgenes, and administration routes, and their effects on peritoneal fibrosis in vivo are summarized in Table 1.

3.1. Viral vectors

Various viral vectors have been investigated for peritoneal fibrosis, including adeno-viral, adeno-associated viral (AAVs), and retroviral vectors.

3.2. Adeno-viral vectors

Adeno-viral vectors are one of the most widely studied viral vectors for gene therapy of peritoneal fibrosis in vivo. Adeno-viral vectors are double-stranded, non-enveloped DNA viral vectors of 70–90 nm in diameter, with a genome of 36–38 kb [46,47]. Transgenes can be inserted into the DNA sequence of adeno-viral vectors [46,47], which are then transfected into cells via receptor-mediated endocytosis [46,47]. Adeno-viral vectors have many advantages in terms of gene delivery, including high transduction efficiency and a large capacity for transgene insertion into their DNA. However, the high expression efficiency of transgenes delivered using adeno-viral vectors is transient because the transgenes are not integrated into the host genome by these vectors [46,47]. However, adeno-viral vectors have been reported to deliver transgenes to the peritoneal membrane with high efficiency in peritoneal fibrosis rodent models, and intraperitoneally administration of adeno-viral vectors expressing the angiogenesis inhibitor, angioatin, inhibited collagen accumulation by inhibiting angiogenesis in rodent models [34,35]. Another study reported that intraperitoneal administration of adeno-viral vectors expressing decorin, which blocks TGF-β signaling, inhibited collagen accumulation in the peritoneum but failed to improve the ultrafiltration rate of the peritoneal membrane in a rat peritoneal fibrosis model [35]. Intraperitoneal administration of adeno-viral vectors expressing bone morphogenetic protein-7 (BMP-7), which is an anti-fibrotic molecule, was also shown to ameliorate peritoneal fibrosis in a rat model [36]. In that study, adeno-viral vector-mediated BMP-7 delivery maintained increased expression levels of BMP-7 in the peritoneum for up to
14 days after administration [36], and inhibited mesothelial–mesenchymal transition of cultured human peritoneal mesothelial cells [36].

### 3.3. Adeno-associated viral vectors

AAVs are single-stranded, non-enveloped DNA viral vectors 18–26 nm in diameter, with a genome of 4–5 kb [46,48,49]. AAVs can deliver transgenes into both dividing and non-dividing cells, and can incorporate their transgenes into the host genome [46,48,49]. Intraperitoneal administration of AAVs expressing decorin significantly inhibited peritoneal fibrosis, associated with preserved peritoneal cell size, decreased peritoneal thickness, and decreased expression of α-SMA in the peritoneum in a mouse peritoneal fibrosis model [37].

### 3.4. Retroviral vectors

Retroviral vectors are enveloped RNA viral vectors 80–130 nm in diameter, with a genome of 8–11 kb [50]. Retroviral vectors can deliver transgenes into the cell via an interaction between their envelope and cell surface receptors [50]. Unlike adenoviral vectors, retroviral vectors only deliver transgenes into dividing cells [50]. They can incorporate transgenes into the host genome and are therefore capable of long-term transgene expression [38,50]. Cultured human peritoneal mesothelial cells transfected with small interfering RNA (siRNA) targeted to connective tissue growth factor (CTGF) using retroviral vectors knocked down CTGF expression and inhibited extracellular matrix production, including fibronectin, collagen I, and laminin, as well as vascular endothelial growth factor expression under stimulation by TGF-β [38]. These results suggest that retroviral vector-mediated CTGF knockdown in peritoneal mesothelial cells may be a promising tool for preventing peritoneal fibrosis *in vivo*. However, the therapeutic effects of retroviral vector-mediated transgene delivery on peritoneal fibrosis have not been investigated *in vivo*.

### 4. Non-viral vectors

Several studies have reported on the possible effects of gene therapies using non-viral vectors for the treatment of peritoneal fibrosis. Non-viral vectors have the advantages of less immunogenicity and toxicity than viral vectors when administered *in vivo*. In addition, their preparation is relatively simple compared with viral vectors. Non-viral vectors used for the treatment of peritoneal fibrosis *in vivo* include liposome nanoparticles [39], gold nanoparticles [37], and cationic gelatin nanoparticles [40], which have been shown to deliver transgenes to the peritoneum effectively in peritoneal fibrosis animal models and have demonstrated efficacy *in vivo* (Figure 2) [37,39,40].

#### 4.1. Liposome nanoparticles

Liposome nanoparticles consist of phospholipids and cholesterol, which are the main components of the cell membrane, and thus show high biocompatibility [39,51,52]. Liposome nanoparticles have been reported to deliver transgenes to the peritoneal membrane, and demonstrated therapeutic efficacy in a mouse peritoneal fibrosis model.
| Vector                  | Transgene          | Administration route | Effects                                                                 | Authors (published year) | Reference No. |
|------------------------|--------------------|----------------------|-------------------------------------------------------------------------|--------------------------|---------------|
| Virus vectors          | Adenovirus         | Angiostatin-DNA      | Intraperitoneal injection Ameliorated peritoneal fibrosis by inhibiting angiogenesis | Hoff and Margetts (2006) | [34]          |
|                        | Adenovirus         | Angiostatin-DNA      | Intraperitoneal injection Ameliorated peritoneal fibrosis by inhibiting angiogenesis | Mangetti et al. (2002)   | [35]          |
|                        | Adenovirus         | Decorin-DNA          | Intraperitoneal injection Inhibited collagen accumulation in peritoneum without improving ultrafiltration ability | Mangetti et al. (2002)   | [35]          |
|                        | Adenovirus         | BMP-7-DNA            | Intraperitoneal injection Ameliorated peritoneal fibrosis                | Yu et al. (2009)         | [36]          |
|                        | AAV                | Decorin-DNA          | Intraperitoneal injection Inhibited peritoneal fibrosis with preservation of peritoneal cell size, decreased peritoneal thickness, and decreased expression of α-SMA | Chaudhary et al. (2014)  | [37]          |
| Retrovirus             | CTGF-siRNA         | Applied to cultured human peritoneal mesothelial cells Inhibited production of the extracellular matrix such as fibronectin, collagen I and laminin and VEGF expression under stimulation of TGF-β1 | Xiao et al. (2010)       | [38]          |
| Non-viral vectors      | Liposome nanoparticles | TGF-β1-siRNA        | Intraperitoneal injection Inhibited TGF-β1 expression in peritoneum, and inhibited peritoneal fibrosis with decreased proliferation of α-SMA-positive myofibroblasts | Yoshizawa et al. (2015)  | [39]          |
| Gold nanoparticles     | Decorin-DNA        | Intraperitoneal injection Inhibited peritoneal fibrosis | Chaudhary et al. (2014) | [37]          |
| Cationic gelatin nanoparticle | HSP47-siRNA    | Intraperitoneal injection Inhibited expression of HSP47 on peritoneum, and inhibited peritoneal fibrosis with decreased expression of type III collagen, TGF-β1, α-SMA, and MCP-1 | Obata et al. (2012) | [40]          |
| Naked, artificial, modified oligonucleotides | None               | HSP47-antisense oligonucleotides | Intraperitoneal injection Inhibited expression of HSP47, and inhibited peritoneal fibrosis with decreased expression of types I and II collagen and α-SMA, and inhibited macrophage infiltration | Nishino et al. (2003) | [41]          |
| Ultrasound-microbubble-mediated transfer | None              | MicroRNA-21-5p-inhibitor-BNA | Intraperitoneal injection Inhibited peritoneal fibrosis with increased expression of PPAR-α | Morishita et al. (2016) | [42]          |
|                        | None               | Smad7-plasmid DNA   | Intraperitoneal injection Inhibited peritoneal fibrosis | Guo et al. (2007) | [43]          |
|                        | None               | MicroRNA-30a         | Intraperitoneal injection Inhibited peritoneal fibrosis with inhibition of Smad signaling pathway | Zhou et al. (2013)       | [44]          |
|                        | None               | MicroRNA-29b         | Intraperitoneal injection Inhibited peritoneal fibrosis with inhibition of TGF-β1 signaling pathway | Yu et al. (2014)         | [45]          |

BMP-7: bone morphogenic protein-7; AAV: adeno-associated viral vector; α-SMA: α-smooth muscle actin; CTGF: connective tissue growth factor; VEGF: vascular endothelial growth factor; IκB-α: I-kappa-B-alpha; TGF-β1: transforming growth factor-β1; HSP47: heat shock protein 47; MCP-1: monocyte chemoattractant protein-1; PPAR-α: peroxisome proliferator-activated receptor; Smad7; mothers against decapentaplegic homolog 7.
fibrosis model [39]. Intraperitoneal administration of liposome nanoparticles encapsulating TGF-β1-siRNA knocked down TGF-β1 expression in the peritoneum and inhibited peritoneal fibrosis, associated with decreased proliferation of α-SMA-positive myofibroblasts derived from different cell types, including mesothelial and bone marrow-derived cells [39].

4.2. Gold nanoparticles

Gold nanoparticles comprise a colloidal gold suspension in a fluid and have demonstrated high stability, low toxicity, and low immunogenicity [53]. They were shown to deliver transgenes to the peritoneum for the treatment of peritoneal fibrosis in vivo [37]. Intraperitoneal administration of plasmid DNA expressing decorin with gold nanoparticles inhibited peritoneal fibrosis by inhibiting the effects of TGF-β1 in a rat peritoneal fibrosis model [37].

4.3. Cationic gelatin nanoparticles

Gelatin is a protein derived from collagen [54]. Cationic gelatin nanoparticles are produced chemically by introducing cations such as ethylenediamine, putrescine, spermidine, or spermine to the carbohydrate group of gelatin, and have been shown to protect transgenes against degradation in vivo [40]. The release rate of transgenes from cationic gelatin nanoparticles can be modulated by changing the degradability of the gelatins [40]. Cationic gelatin nanoparticles demonstrated therapeutic efficacy in a mouse peritoneal fibrosis model [40]. Intraperitoneal single injection of heat shock protein 47 (HSP47)-siRNA entrapped with cationic gelatin nanoparticles was shown to release HSP47-siRNA continuously over 21 days as a result of degradation of the gelatin nanoparticles [40]. They also significantly inhibited both expression of HSP47 in the peritoneum and peritoneal fibrosis, together with decreased expression of type III collagen, TGF-β1, α-SMA, and monocyte chemoattractant protein-1 in peritoneal tissue in a mouse peritoneal fibrosis model [40].

5. Other methods of gene therapy for renal fibrosis in vivo

Intraperitoneal injection of naked, artificial, modified oligonucleotides has shown therapeutic effects against peritoneal fibrosis in vivo [41,42]. Ultrasound-mediated transgene delivery also resulted in effective delivery of transgenes to the peritoneum and therapeutic effects against peritoneal fibrosis in vivo [43].

5.1. Naked artificial modified oligonucleotides

Intraperitoneal injection of naked, antisense oligonucleotides and artificially synthesized bridged nucleic acids (BNA) inhibited peritoneal fibrosis in vivo [41,42]. Antisense oligonucleotides are short, artificial synthetic 15–25 nt oligonucleotides [55], which include phosphorothioate linkages that confer nuclease resistance to enhance intracellular stability [55]. BNAs are modified RNA nucleotides including a molecule with a five- or six-membered bridged structure with a fixed C3′-endo sugar puckering [56]. BNAs increase the binding affinities to target oligonucleotides and transgene stability [56]. Intraperitoneal injection of naked HSP47 antisense oligonucleotides inhibited peritoneal fibrosis in a rat model, associated with reduced expression levels of HSP47, types I and III collagen, and α-SMA, as well as reducing the number of infiltrating macrophages in a rat peritoneal fibrosis model [41]. In that study, HSP47 antisense oligonucleotides were shown to inhibit HSP47 expression in cells, including fibroblasts, in the peritoneal sub-mesothelial zone [41]. Intraperitoneal injection of naked, artificially synthesized BNAs of microRNA (miRNA)-21 inhibitor inhibited peritoneal fibrosis by inhibiting proliferation of myofibroblasts from different origins, such as mesothelial cells, bone marrow-derived cells, and endothelial cells, in addition to resident fibroblasts, and increased expression of the miRNA-21 target gene, peroxisome proliferator-activated receptor, in a peritoneal fibrosis mouse model [42].

5.2. Ultrasound-microbubble-mediated transfer

Ultrasound-microbubble-mediated gene transfer has been reported to deliver transgenes to the peritoneum and to have therapeutic effects against peritoneal fibrosis in vivo [43]. Plasmid DNA expressing mothers against decapentaplegic homolog 7 (Smad7) mixed with albumin-stabilized perfluorocarbon gas microbubbles was injected intraperitoneally, and the surface of the abdomen was then exposed to ultrasound from the costal margin to the pubic symphysis, resulting in overexpression of Smad7 in the peritoneum, adipose tissue, mesentery, greater omentum, and spleen, but not in the liver, kidney, pancreas, or intestine in a rat model [43]. This delivery method was shown to maintain overexpression of Smad7 in the peritoneum for up to 2 weeks and inhibited peritoneal fibrosis in a rat peritoneal fibrosis model [43]. Ultrasound-microbubble-mediated delivery of plasmid DNA expressing miRNA-29b and miRNA-30a to the peritoneum induced overexpression of the respective miRNAs in the peritoneum and inhibited mesothelial–mesenchymal transition of peritoneal mesothelial cells, resulting in inhibition of peritoneal fibrosis in a mouse peritoneal fibrosis model, by inhibiting TGF-β1 and Snail signaling pathways, respectively [44,45].
Various delivery systems for gene therapy of peritoneal fibrosis have been developed. However, their long-term efficacy, effects on other organs, and possible adverse effects remain unclear. In addition, no study has yet reported on vectors that can specifically target the peritoneum. Further studies are therefore needed to investigate these aspects and to develop delivery systems suitable for delivering transgenes exclusively to the peritoneum.

Acknowledgments

The authors thank the members of the Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University.

Authors’ contributions

Yusuke Igarashi drafted the manuscript. Taro Hoshino, Susumu Ookawara, and Kenichi Ishibashi supervised the manuscript. Yoshiyuki Morishita conceived the content of and supervised the manuscript. All authors contributed towards preparing the manuscript and agree to be accountable for all aspects of the work.

Disclosure statement

No potential conflict of interest was reported by the authors.

Notes on contributors

Yusuke Igarashi is a medical staff member of the Division of Nephrology, Department of Internal Medicine, Jichi Medical University. His research area is nephrology and dialysis.

Taro Hoshino is an assistant professor of the Division of Nephrology, Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University. His research area is nephrology and dialysis.

Susumu Ookawara is an associate professor of the Division of Nephrology, Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University. His research area is nephrology and dialysis.

Kenichi Ishibashi is a professor of the Department of Medical Physiology, Meiji Pharmaceutical University. His research area is nephrology and water channels, aquaporins.

Yoshiyuki Morishita is a professor of the Division of Nephrology, Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University. His research areas are nephrology, dialysis, gene delivery for the treatment of renal diseases, and analysis of microRNA profiling for the development of renal disease.

References

[1] Krediet RT. Advances in peritoneal dialysis. Minerva Urol Nefrol. 2007;59:251–260. Epub 2007 Oct 4.
[2] McDonald SP, Marshall MR, Johnson DW, et al. Relationship between dialysis modality and mortality. J Am Soc Nephrol. 2009;20:155–163. Epub 2008 Dec 19.
[3] Di Paolo N, Sacchi G. Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): an in vivo model for the study of diabetic microangiopathy. Perit Dial Int. 1989;9:41–45. Epub 1989 Jan 1.
[4] Hung KY, Huang JW, Tsai TJ, et al. Natural changes in peritoneal equilibration test results in continuous ambulatory peritoneal dialysis patients: a retrospective, seven year cohort survey. Artif Organs. 2000;24:261–264. Epub 2000 May 18.
[5] Van Biesen W, Vanholder R, Lameire N. The role of peritoneal dialysis as the first-line renal replacement modality. Perit Dial Int. 2000;20:375–383. Epub 2000 Sep 28.
[6] Krediet RT, Lindholm B, Rippe B. Pathophysiology of peritoneal membrane failure. Perit Dial Int. 2000;20 Suppl 4:S22–S42. Epub 2000 Dec 1.
[7] Gandhi VC, Humayun HM, Ing TS, et al. Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. Arch Intern Med. 1980;140:1201–1203. Epub 1980 Sep 1.
[8] Ronco C, Feriani M, Chiaramonte S, et al. Pathophysiology of ultrafiltration in peritoneal dialysis. Perit Dial Int. 1990;10:119–126. Epub 1990 Jan 1.
[9] Margetts PJ, Bonniaud P. Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int. 2003;23:530–541. Epub 2004 Jan 2.
[10] Devuyst O, Margetts PJ, Topley N. The pathophysiology of the peritoneal membrane. J Am Soc Nephrol. 2010;21:1077–1085. Epub 2010 May 8.
[11] Loureiro J, Aguilar A, Selgas R, et al. Blocking TGF-β1 protects the peritoneal membrane from dialysate-induced damage. J Am Soc Nephrol. 2011;22:1682–1695. Epub 2011 Jul 12.
[12] Wong JKL, Mohseni R, Hamidieh AA, et al. Will nanotechnology bring new hope for gene delivery? Trends Biotechnol. 2017;35:434–451. Epub 2017 Jan 22.
[13] Tang Y, Zeng Z, He X, et al. siRNA crosslinked nanoparticles for the treatment of inflammation-induced liver injury. Adv Sci (Weinh). 2017;4:1600228. Epub 2017 Mar 3.
[14] Lee HY, Park HC, Seo BJ, et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int. 2005;25:248–255. Epub 2005 Jun 29.
[15] Hirahara I, Ishibashi Y, Kaname S, et al. Methylglyoxal induces peritoneal thickening by mesenchymal-like cell responses.
mesothelial cells in rats. Nephrol Dial Transplant. 2009;24:437–447. Epub 2008 Sep 16.

[16] Nilsson-Thorell CB, Muscalu N, Andrén AH, et al. Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes. Perit Dial Int. 1993;13:208–213. Epub 1993 Jan 1.

[17] Schalkwijk CG, Posthuma N, ten Brink HJ, et al. Induction of 1,2-dicarbonyl compounds, intermediates in the formation of advanced glycation end-products, during heat-sterilization of glucose-based peritoneal dialysis fluids. Perit Dial Int. 1999;19:325–333. Epub 1999 Oct 3.

[18] Nakayama M, Saki A, Numata M, et al. Hyper-vascular change and formation of advanced glycation end-products in the peritoneum caused by methylglyoxal and the effect of an anti-oxidant, sodium sulfite. Am J Nephrol. 2003;23:390–394. Epub 2003 Oct 11.

[19] De Vriese AS, Tilton RG, Mortier S, et al. Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uroaemia. Nephrol Dial Transplant. 2006;21:2549–2555. Epub 2006 Jun 8.

[20] Ito T, Yorioka N, Yamamoto M, et al. Effect of glucose on intercellular junctions of cultured human peritoneal mesothelial cells. J Am Soc Nephrol. 2000;11:1969–1979. Epub 2000 Oct 29.

[21] Offner FA, Feichtinger H, Stadlmann S, et al. Transforming growth factor-beta synthesis by human peritoneal mesothelial cells. Induction by interleukin-1. Am J Pathol. 1996;148:1679–1688. Epub 1996 May 1.

[22] Loureiro J, Schulte M, Aguilera A, et al. BMP-7 blocks mesenchymal conversion of mesothelial cells and prevents peritoneal damage induced by dialysis fluid exposure. Nephrol Dial Transplant. 2010;25:1098–1108. Epub 2010 Jan 14.

[23] Peinado H, Quintanilla M, Cano A. Transforming growth factor-beta1 induces snail transcription factor in epithelial cell line: mechanisms for epithelial mesenchymal transitions. J Biol Chem. 2003;278:21113–21123. Epub 2003 Apr 1.

[24] Margetts PJ, Bonniaud P, Liu L, et al. Transient overexpression of TGF-β1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol. 2005;16:425–436. Epub 2004 Dec 14.

[25] Yokoi H, Kasahara M, Mori K, et al. Peritoneal fibrosis and high transport are induced in mildly pre-injured peritoneum by 3,4-dideoxyglucosone-3-ene in mice. Perit Dial Int. 2013;33:143–154. Epub 2012 Nov 6.

[26] Nakamura S, Niwa T. Advanced glycation end-products and peritoneal sclerosis. Semin Nephrol. 2004;24:502–505. Epub 2004 Oct 19.

[27] Fujimori A, Naito H, Miyazaki T, et al. Elevation of interleukin 6 in the dialysate reflects peritoneal stimuli and deterioration of peritoneal function. Nephron. 1996;74:471–472. Epub 1996 Jan 1.

[28] Carozzi S, Nasini MG, Ravera M, et al. Peritoneal dialysis effluent, cytokine levels, and peritoneal mesothelial cell viability in CAPD: a possible relationship. Adv Perit Dial. 1997;13:7–12. Epub 1997 Jan 1.

[29] Lai KN, Lai KB, Lam CW, et al. Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 2003;35:644–652. Epub 2000 Mar 31.

[30] Maksic D, Vasilijic S, Colic M, et al. Systemic and intra-peritoneal proinflammatory cytokine profiles in patients on continuous ambulatory peritoneal dialysis. Adv Perit Dial. 2009;25:50–55. Epub 2009 Nov 6.

[31] Kawanishi H, Fujimori A, Tsuchida K, et al. Markers in peritoneal effluent for withdrawal from peritoneal dialysis: multicenter prospective study in Japan. Adv Perit Dial. 2005;21:134–138. Epub 2006 May 12.

[32] Bachus KE, Doty E, Haney AF, et al. Differential effects of interleukin-1 alpha, tumor necrosis factor-alpha, indomethacin, hydrocortisone, and macrophage co-culture on the proliferation of human fibroblasts and peritoneal mesothelial cells. J Soc Gynecol Investig. 1995;2:636–642. Epub 1995 Jul 1.

[33] Cunliffe IA, Richardson PS, Rees RC, et al. Effect of TNF, IL-1, and IL-6 on the proliferation of human Tenon's capsule fibroblasts in tissue culture. Br J Ophthalmol. 1995;79:590–595. Epub 1995 Jun 1.

[34] Hoff CM, Margetts PJ. Adenovirus-based transient expression systems for peritoneal membrane research. Perit Dial Int. 2006;26:547–558. Epub 2006 Sep 16.

[35] Margetts PJ, Gyory FF, Kolb M, et al. Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol. 2002;13:721–728. Epub 2002 Feb 22.

[36] Yu M-A, Shin K-S, Kim JH, et al. HGF and BMP-7 ameliorate high glucose-induced epithelial-to-mesenchymal transition of peritoneal mesothelium. J Am Soc Nephrol. 2009;20:567–581. Epub 2009 Feb 6.

[37] Chaudhary K, Moore H, Tandon A, et al. Nanotechnology and adenovirus-based decorin gene therapy ameliorates peritoneal fibrosis. Am J Physiol Renal Physiol. 2014;307:F777–F782. Epub 2014 Jul 25.

[38] Xiao L, Sun L, Liu F-Y, et al. Connective tissue growth factor knockdown attenuated matrix protein production and vascular endothelial growth factor expression induced by transforming growth factor-beta1 in cultured human peritoneal mesothelial cells. Ther Apher Dial. 2010;14:27–34. Epub 2010 May 5.

[39] Yoshizawa H, Morishita Y, Watanabe M, et al. TGF–β1 siRNA delivery with nanoparticles inhibits peritoneal fibrosis. Gene Ther. 2015;22:333–340. Epub 2015 Jan 9.

[40] Obata Y, Nishino T, Kushibiki T, et al. HSP47 siRNA conjugated with cationized gelatin microspheres suppresses peritoneal fibrosis in mice. Acta Biomater. 2012;8:2688–2696. Epub 2012 Apr 11.

[41] Nishino T, Miyazaki M, Abe K, et al. Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress peritoneal fibrosis in rats. Kidney Int. 2003;64:887–896. Epub 2003 Aug 13.

[42] Morishita Y, Yoshizawa H, Watanabe M, et al. MicroRNA expression profiling in peritoneal fibrosis. Transl Res. 2016;169:47–66. Epub 2015 Dec 1.

[43] Guo H, Leung JC, Chan LY, et al. Ultrasound-contrast agent mediated naked gene delivery in the peritoneal cavity of adult rat. Gene Ther. 2007;14:1712–1720. Epub 2007 Oct 26.

[44] Zhou Q, Yang M, Lan H, et al. miR-30a negatively regulates TGF-β1-induced epithelial-mesenchymal transition and peritoneal fibrosis by targeting Smad1. Am J Pathol. 2013;183:808–819. Epub 2013 Jul 9.

[45] Yu J-W, Duan W-J, Huang X-R, et al. MicroRNA-29b inhibits peritoneal fibrosis in a mouse model of peritoneal dialysis. Lab Invest. 2014;94:978–990. Epub 2014 Jul 22.

[46] Kamimura K, Suda T, Zhang G, et al. Advances in gene delivery systems. Pharmaceut Med. 2011;25:293–306. Epub 2011 Dec 28.

[47] Wold WSM, Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther. 2013;13:421–433. Epub 2013 Nov 28.
[48] Borel F, Kay MA, Mueller C. Recombinant AAV as a platform for translating the therapeutic potential of RNA interference. Mol Ther. 2014;22:692–701. Epub 2013 Dec 20.

[49] Daya S, Berns K. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev. 2008;21:583–593. Epub 2008 Oct 16.

[50] Barquinero J, Eixarch H, Perez-Melgosa M. Retroviral vectors: new applications for an old tool. Gene Ther. 2004;11 Suppl 1:S3–S9. Epub 2004 Sep 30.

[51] Kikuchi A, Aoki Y, Sugaya S, et al. Development of novel cationic liposomes for efficient gene transfer into peritoneal disseminated tumor. Hum Gene Ther. 1999;10:947–955. Epub 1999 May 1.

[52] Sato Y, Murase K, Kato J, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nature Biotechnology. 2008;26:431–442.

[53] Chithrani BD, Ghazani AA, Chan WCW. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 2006;6:662–668. Epub 2006 Apr 13.

[54] Djagny KB, Wang Z, Xu S. Gelatin: a valuable protein for food and pharmaceutical industries: review. Crit Rev Food Sci Nutr. 2001;41:481–492. Epub 2001 Oct 11.

[55] Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther. 2002;1:347–355. Epub 2002 Dec 20.

[56] Wahlestedt C, Salmi P, Good L, et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci U S A. 2000;97:5633–5638. Epub 2000 May 11.